Mesoblast Posts $115M in First Full Year of Ryoncil Revenue
Event summary
- Mesoblast reported $36M in Ryoncil net revenue for Q4 2026, totaling $115M for the first full year post-FDA approval.
- The company treated at least 300 patients in its pivotal Phase 3 trial for chronic low back pain with rexlemestrocel-L.
- Mesoblast secured IND clearance from the FDA to evaluate Ryoncil in ambulatory children aged 5-9 years with Duchenne muscular dystrophy (DMD).
- The company acquired an exclusive worldwide license to a patented chimeric antigen receptor (CAR) technology platform for precision-enhanced MSC products.
The big picture
Mesoblast's strong first-year revenue from Ryoncil underscores the growing adoption of cellular therapies in severe inflammatory diseases. The company's strategic focus on expanding indications into larger adult markets and leveraging next-generation MSC technologies positions it to capitalize on unmet medical needs. However, its success hinges on navigating regulatory hurdles and demonstrating clinical efficacy across multiple indications.
What we're watching
- Regulatory Milestones
- The pace at which Mesoblast advances its registrational trial for Ryoncil in adults with SR-aGvHD and secures additional FDA clearances will determine the timeline for label extensions.
- Clinical Trial Outcomes
- Whether the Phase 3 trial results for rexlemestrocel-L in chronic low back pain meet primary endpoints will influence its BLA filing success and market potential.
- Technology Integration
- How effectively Mesoblast integrates CAR technology into its MSC products to enhance potency for conditions like ulcerative colitis and Lupus Nephritis will shape its competitive edge.
Related topics